In November 2019, DQS held an ISO 27001 certification ceremony with SAMSUNG BIOLOGICS, the largest Korean pharmaceutical contract manufacturer (CMO) and a major subsidiary of the Samsung Group.
DQS successfully conducted the certification audit at Samsung Biologics, a leading contract manufacturer engaged in the research, development, and commercialization of biopharmaceutical products worldwide. DQS auditors examined the company’s security systems for four months, considering 114 criteria across 14 categories related to information technology, security and management.
According to the company, acquiring certification is a significant step because a CMO business has to deal with sensitive information about its clients when developing products for them. This information is usually related to the clients’ core competencies. “Now that we have this certification, our global clients can have more trust in our security systems,” Samsung Biologics official Kim Yong-shin said in a statement.
Dr. Tae Han Kim, CEO of Samsung Biologics added, “We are very proud to be the first CDMO in our industry to attain this certification, which demonstrates how much value, rigor, and care we place in managing our clients’ information assets. To be given awarded this personally by Ambassador Auer is especially meaningful given our client and partner relationships with the best global companies.”
ISO 27001 is an information security management system standard. Achieving ISO 27001:2013 certification will testify to customers and stakeholders that the organization’s information security management system is in place according to an international standard.
DQS is providing certification service and training courses against the 27001 standards. Contact us to learn more about how you can benefit from the certification to ISO 27001 and what supports DQS can offer.